Cardiol Therapeutics Inc. (CRDL)
| Previous Close | 1.9100 |
| Open | 1.9300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.8500 - 1.9400 |
| 52 Week Range | 0.7000 - 3.1200 |
| Volume | |
| Avg. Volume | 420,129 |
| Market Cap | 149.45M |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3200 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.97 |
NewsfileCardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program. Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for th
NewsfileCardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to th
